What is Citius Oncology, Inc.'s change in AR?

Citius Oncology, Inc. (CTOR) reported change in AR of $4.05M in Q4 2025.

What does change in AR mean?

Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.

Citius Oncology, Inc. CTOR Change in AR

Change in AR at other companies

Merck & Co.MRK

$272.5M+347%

Delcath SystemsDCTH

$2.42M-20.9%

Iovance Biotherapeutics, Inc.IOVA

-$690K-143%

ImmunityBio, Inc.IBRX

$700K-95.2%

Gilead SciencesGILD

-$134M-69.6%

United TherapeuticsUTHR

-$38.2M-189%

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s change in AR?: Citius Oncology, Inc. (CTOR) reported change in AR of $4.05M in Q4 2025.
What does change in AR mean?: Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.